Ultragenyx Pharmaceutical Inc. SEC filings RARE

Ultragenyx Pharmaceutical Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jul 20, 2015. Its latest annual report, Form ARS, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (acquisition or sale of assets, results of operations, exit or restructuring costs). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Mar 27, 2026 Dec 31, 2025
10-K Annual report Feb 18, 2026 Dec 31, 2025
ARS Annual report to shareholders Mar 28, 2025 Dec 31, 2024
10-K Annual report Feb 19, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 26, 2024 Dec 31, 2023
10-K Annual report Feb 21, 2024 Dec 31, 2023
10-K Annual report Feb 17, 2023 Dec 31, 2022
10-K Annual report Feb 15, 2022 Dec 31, 2021
10-K Annual report Feb 12, 2021 Dec 31, 2020
10-K Annual report Feb 14, 2020 Dec 31, 2019
10-K Annual report Feb 20, 2019 Dec 31, 2018
10-K Annual report Feb 21, 2018 Dec 31, 2017
10-K Annual report Feb 17, 2017 Dec 31, 2016
10-K Annual report Feb 26, 2016 Dec 31, 2015

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RARE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Novato, CA
SEC filer status
Large accelerated filer
SEC CIK
1515673

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.